digiDEM Bavaria HIGHLIGHT_04: New Dementia Medications – Are the New Medications Affordable?
In the fourth edition of our new special newsletter SCHLAGLICHT – New Drugs for Dementia, Florian Weidinger, research associate at digiDEM Bayern, deals with the publication "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint" by the research team led by Professor Linus Jönsson from the Karolinska Institutet in Sweden. In the journal The Lancet…
